Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects

A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Studies to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects

This study will be conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending oral doses of E2082 in healthy Japanese adult and elderly male participants, and to evaluate the safety, tolerability, and PK of multiple ascending oral doses of E2082 in healthy Japanese and Caucasian adult male participants.

Study Overview

• Status: Terminated
• Conditions: Healthy Participants
• Intervention / Treatment: Drug: E2082; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 118
• Phase: Phase 1

Contacts and Locations

Study Locations

• Japan
  • Tokyo
    • Sumida-ku, Tokyo, Japan
      • Eisai Trial Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

Participants must meet all of the following criteria to be included in this study:

• Non-smoking, age ≥20 years and <55 years old adult male (Cohorts 1 to 9 of Part A and all cohorts of Part B), or age ≥55 years and ≤85 years old elderly male (only Cohort 10 of Part A) at the time of informed consent. To be considered non-smokers, participants must have discontinued smoking for at least 4 weeks before dosing.
• Body mass index ≥18 and <30 kilograms per meters squared at Screening

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from this study:

• Evidence of disease that may influence the outcome of the study within 4 weeks before dosing; example, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism
• Any history of gastrointestinal surgery that may affect pharmacokinetic profiles of E2082, example, hepatectomy, nephrectomy, and digestive organ resection
• Any clinically abnormal symptom or organ impairment found by medical history, physical examinations, vital signs, electrocardiogram finding, or laboratory test results that require medical treatment at Screening

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: E2082; E2082 will be administered as a solution (0.2 milligram [mg]), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg E2082 solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg E2082 tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg E2082 under fasted conditions, and then they will receive 5 mg E2082 under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) E2082 tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg tablets once daily for 10 days. E2082 will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.	Drug: E2082; Solution (0.2 mg) or tablet (0.5 mg and 5 mg).
Placebo Comparator: E2082-matched placebo; Matched placebo will be administered as a solution (0.2 mg), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg matched placebo solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg matched placebo tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg matched placebo under fasted conditions, and then they will receive 5 mg matched placebo under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) matched placebo tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg matched placebo tablets once daily for 10 days. Matched placebo will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.	Drug: Placebo; Solution (0.2 mg) or tablet (0.5 mg and 5 mg) matched to E2082.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part A: Mean value of the maximum observed concentration (Cmax) of E2082 under a fasted state for the single ascending dose (SAD) Cohorts 1-10	Cmax is the maximum observed concentration of E2082 in the plasma that is measured after a dose.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), and 168 (Day 8) hours postdose for all cohorts. Additionally, 240 (Day 11) and 336 (Day 15) hours postdose for Cohort 4 or later.
Part A: Mean value of Cmax of E2082 under a fed state for the SAD Cohort 5	Cmax is the maximum observed concentration of E2082 in the plasma that is measured after a dose.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose
Part A: Mean value of the time at which the highest plasma concentration (Tmax) of E2082 occurs under a fasted state for the SAD Cohorts 1-10	Tmax is the time at which the highest concentration of E2082 occurs.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), and 168 (Day 8) hours postdose for all cohorts. Additionally, 240 (Day 11) and 336 (Day 15) hours postdose for Cohort 4 or later.
Part A: Mean value of Tmax of E2082 under fed state for the SAD Cohort 5	Tmax is the time at which the highest concentration of E2082 occurs.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose
Part A: Mean value of the area under the concentration-time curve from zero time to 24 hours after dosing (AUC[0-24h]) under a fasted state for the SAD Cohorts 1-10	AUC(0-24h) represents the total drug exposure from zero time to 24 hours after dosing.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose
Part A: Mean value of AUC(0-24h) under a fed state for the SAD Cohort 5	AUC(0-24h) represents the total drug exposure from zero time to 24 hours after dosing.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose
Part A: Mean value of AUC from zero time to the time of the last quantifiable concentration (AUC[0-t]) under a fasted state for the SAD Cohorts 1-10	AUC(0-t) represents the total drug exposure from zero time to the time of the last quantifiable concentration.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), and 168 (Day 8) hours postdose for all cohorts. Additionally, 240 (Day 11) and 336 (Day 15) hours postdose for Cohort 4 or later.
Part A: Mean value of AUC(0-t) under a fed state for the SAD Cohort 5	AUC(0-t) represents the total drug exposure from zero time to the time of the last quantifiable concentration.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose
Part A: Mean value of AUC from zero time to 72 hours after dosing (AUC[0-72h]) under a fasted state for the SAD Cohorts 1-10	AUC(0-72h) represents the total drug exposure from zero time to 72 hours after dosing.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, and 72 hours postdose
Part A: Mean value of AUC(0-72h) under a fed state for the SAD Cohort 5	AUC(0-72h) represents the total drug exposure from zero time to 72 hours after dosing.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, and 72 hours postdose
Part A: Mean value of AUC from zero time to 96 hours after dosing (AUC[0-96h]) under a fasted state for the SAD Cohorts 1-10	AUC(0-96h) represents the total drug exposure from zero time to 96 hours after dosing.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours postdose
Part A: Mean value of AUC(0-96h) under a fed state for the SAD Cohort 5	AUC(0-96h) represents the total drug exposure from zero time to 96 hours after dosing.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours postdose
Part A: Mean value of AUC from zero time extrapolated to infinite time (AUC[0-inf]) under a fasted state for the SAD Cohorts 1-10	AUC(0-inf) represents the total drug exposure from zero time extrapolated to infinite time.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), and 168 (Day 8) hours postdose for all cohorts. Additionally, 240 (Day 11) and 336 (Day 15) hours postdose for Cohort 4 or later.
Part A: Mean value of AUC(0-inf) under a fed state for the SAD Cohort 5	AUC(0-inf) represents the total drug exposure from zero time extrapolated to infinite time.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose
Part A: Mean value of terminal elimination phase half-life (t½) of E2082 under a fasted state for the SAD Cohorts 1-10	t½ is the time required for the concentration or amount of drug in the body to be reduced to exactly one-half of a given concentration or amount.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), and 168 (Day 8) hours postdose for all cohorts. Additionally, 240 (Day 11) and 336 (Day 15) hours postdose for Cohort 4 or later.
Part A: Mean value of t½ of E2082 under a fed state for the SAD Cohort 5	t½ is the time required for the concentration or amount of drug in the body to be reduced to exactly one-half of a given concentration or amount.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose
Part A: Mean value of apparent total clearance (CL/F) of E2082 under a fasted state for the SAD Cohorts 1-10	CL/F is the apparent total clearance following extravascular (example, oral) administration.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), and 168 (Day 8) hours postdose for all cohorts. Additionally, 240 (Day 11) and 336 (Day 15) hours postdose for Cohort 4 or later.
Part A: Mean value of CL/F of E2082 under a fasted state for the SAD Cohort 5	CL/F is the apparent total clearance following extravascular (example, oral) administration.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose
Part A: Mean value of the apparent volume of distribution at terminal phase of E2082 on Day 1 (Vz/F) under a fasted state for the SAD Cohorts 1-10	The apparent volume of distribution gives information about the amount of drug distributed in body tissue rather than the plasma.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 hours postdose
Part A: Mean value of Vz/F of E2082 on Day 1 under a fed state for the SAD Cohort 5	The apparent volume of distribution gives information about the amount of drug distributed in body tissue rather than the plasma.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 hours postdose
Part B: Mean value of Cmax of E2082 for the multiple ascending dose (MAD) cohorts on Day 1	Cmax is the maximum observed concentration of E2082 in the plasma that is measured after a dose.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose of Day 1
Part B: Mean value of Cmax of E2082 at steady state (Css,max) for the MAD cohorts on Day 10	Cmax is the maximum observed concentration of E2082 in the plasma that is measured after a dose.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 10
Part B: Mean value of the minimum observed concentration (Cmin) of E2082 for the MAD cohorts on Day 1	Cmin is the minimum observed concentration of E2082 in the plasma that is measured after a dose.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose of Day 1
Part B: Mean value of Cmin of E2082 at steady state (Css,min) for the MAD cohorts	Css,min is the minimum observed concentration of E2082 in the plasma that is measured after a dose at steady state.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 10
Part B: Mean value of Tmax of E2082 for the MAD cohorts on Day 1	Tmax is the time at which the highest concentration of E2082 occurs.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose of Day 1
Part B: Mean value of Tmax of E2082 at steady state (Tss,max) for the MAD cohorts	Tss,max is the time at which the highest concentration of E2082 occurs at steady state.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 10
Part B: Mean value of the average steady state concentration (Css,av) of E2082 for the MAD cohorts	The average steady state concentration is calculated as AUC(0-τ)/τ. τ is the dosing interval.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose of Day 10
Part B: Mean value of AUC(0-24h) after dosing on Day 1 for the MAD cohorts	AUC(0-24h) represents the total drug exposure from zero time to 24 hours after dosing.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose of Day 1
Part B: Mean value of AUC(0-τ) for the MAD cohorts	AUC(0-τ) is AUC over the dosing interval on multiple dosing.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 and 24 hours postdose of Day 10
Part B: Mean value of t½ following the last day of dosing for the MAD cohorts	t½ is the time required for the concentration or amount of drug in the body to be reduced to exactly one-half of a given concentration or amount.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 10
Part B: Peak-trough fluctuation (PTF) for the MAD cohorts	PTF is peak to trough fluctuation at steady-state.	Predose at Days 1, 2, 6, 10, 12, 13, and 14. 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose of Day 1. 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 10
Part B: Accumulation ratio for AUC and Cmax (Rac) for the MAD cohorts	Rac (Cmax) is calculated as the ratio of drug concentrations observed during a dosing interval at steady-state divided by drug concentrations seen during the dosing interval after a single (first) dose. Rac (AUC)=steady state AUC(0-τ)/single dose AUC(0- τ), where τ is dosing interval.	Predose at Days 1, 2, 6, 10, 12, 13, and 14. 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose of Day 1. 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 10
Part B: Mean value of apparent total clearance at steady state (CLss/F) for the MAD cohorts on Day 10	CLss/F is the apparent total clearance at steady state following extravascular (example, oral) administration. It is defined as the rate of drug elimination.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 10
Part B: Mean value of Vz/F for the MAD cohorts on Day 10	Vz/F is apparent volume of distribution at terminal phase on Day 10.	Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 10
Part B: Change from baseline in QT interval corrected for heart rate using the Fridericia formula (QTcF)		Baseline and Day 1
Part B: Change from baseline in QT interval corrected for heart rate using the Fridericia formula (QTcF)		Baseline and Day 10

Secondary Outcome Measures

Outcome Measure	Time Frame
Change-from-baseline in heart rate (HR)	Baseline, Days 1 and 10
Change from baseline in PR interval and QRS interval of the Electrocardiogram (ECG)	Baseline, Days 1 and 10
Placebo-corrected change from baseline in HR	Baseline, Days 1 and 10
Placebo-corrected change from baseline in QTcF, PR, QRS interval	Baseline, Days 1 and 10
Number of participants with categorical outliers for HR, PR interval, QRS interval	Baseline up to Day 11
Number of participants with categorical outliers defined as QTcF >450 msec, 480 msec and 500 msec at any timepoint and change-from-baseline QTcF (ΔQTcF) >30 msec (increased by 30 msec) and >60 msec	Baseline up to Day 11
Number of participants with T wave morphology changes	Baseline up to Day 11
Number of participants with U-wave presence	Baseline up to Day 11

Collaborators and Investigators

• Sponsor: Eisai Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): December 21, 2017
• Primary Completion (Actual): February 20, 2020
• Study Completion (Actual): February 20, 2020

Study Registration Dates

• First Submitted: January 10, 2018
• First Submitted That Met QC Criteria: January 10, 2018
• First Posted (Actual): January 18, 2018

Study Record Updates

• Last Update Posted (Actual): June 30, 2021
• Last Update Submitted That Met QC Criteria: June 29, 2021
• Last Verified: June 1, 2021

More Information

Terms related to this study

• Keywords: male; single ascending dose; multiple ascending dose; E2082
• Other Study ID Numbers: E2082-J081-001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No